These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 28811384)
1. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384 [TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2. Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409 [TBL] [Abstract][Full Text] [Related]
4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513 [TBL] [Abstract][Full Text] [Related]
5. Nur77 suppression facilitates androgen deprivation-induced cell invasion of prostate cancer cells mediated by TGF-β signaling. Wu J; Sun H; Yang X; Sun X Clin Transl Oncol; 2018 Oct; 20(10):1302-1313. PubMed ID: 29594945 [TBL] [Abstract][Full Text] [Related]
6. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis. Hu S; Duan YX; Zhou Q; Wang Y; Lu Q IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986 [TBL] [Abstract][Full Text] [Related]
7. Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance. Huang PA; Price DK; Figg WD Cancer Biol Ther; 2018; 19(10):869-870. PubMed ID: 29757697 [TBL] [Abstract][Full Text] [Related]
8. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis. Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606 [TBL] [Abstract][Full Text] [Related]
9. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. Zhu M; Chen Q; Liu X; Sun Q; Zhao X; Deng R; Wang Y; Huang J; Xu M; Yan J; Yu J FEBS J; 2014 Aug; 281(16):3766-75. PubMed ID: 24988946 [TBL] [Abstract][Full Text] [Related]
10. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response. Begemann D; Anastos H; Kyprianou N Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000 [TBL] [Abstract][Full Text] [Related]
11. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Haller AC; Tan W; Payne-Ondracek R; Underwood W; Tian L; Morrison C; Li F Prostate; 2014 May; 74(5):509-19. PubMed ID: 24375440 [TBL] [Abstract][Full Text] [Related]
12. Fararjeh AS; Liu YN Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505 [TBL] [Abstract][Full Text] [Related]
14. Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI. Lee MJ; Heo SC; Shin SH; Kwon YW; Do EK; Suh DS; Yoon MS; Kim JH Int J Biochem Cell Biol; 2013 Aug; 45(8):1869-77. PubMed ID: 23735324 [TBL] [Abstract][Full Text] [Related]
15. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity. Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000 [TBL] [Abstract][Full Text] [Related]
17. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372 [TBL] [Abstract][Full Text] [Related]
18. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5. Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696 [TBL] [Abstract][Full Text] [Related]
19. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803 [TBL] [Abstract][Full Text] [Related]
20. Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis. Chiavarina B; Costanza B; Ronca R; Blomme A; Rezzola S; Chiodelli P; Giguelay A; Belthier G; Doumont G; Van Simaeys G; Lacroix S; Yokobori T; Erkhem-Ochir B; Balaguer P; Cavailles V; Fabbrizio E; Di Valentin E; Gofflot S; Detry O; Jerusalem G; Goldman S; Delvenne P; Bellahcène A; Pannequin J; Castronovo V; Turtoi A Theranostics; 2021; 11(4):1626-1640. PubMed ID: 33408771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]